Breast Cancer: 2022 ASCO Annual Meeting Highlights for the Advanced Practitioner
Jacquelyn Lauria, RN, APN, AOCNP® and Rose DiMarco, PharmD, BCPS, BCOP
J Adv Pract Oncol 2022;13(6):570-578 |
© 2022 Harborside™
Jacquelyn Lauria, RN, APN, AOCNP®, of Rutgers Cancer Institute, discusses results from the DESTINY-BREAST04 trial on HER2-low metastatic breast cancer, findings on sacituzumab govitecan in HR-positive, HER2-negative metastatic breast cancer, and options for disease progression after a CDK4/6 inhibitor. Rose DiMarco, PharmD, BCPS, BCOP, of Thomas Jefferson University Hospital, considers insights provided by a survey on participation in clinical trials among Black patients with metastatic breast cancer.
For access to the full length article, please sign in